ecancermedicalscience

Special Issue

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?

3 Dec 2020
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco

Precision immunotherapy is a crucial approach to improve the efficacy of anti-cancer treatments, particularly in the metastatic setting. In this respect, accurate patient selection takes advantage of the multidimensional integration of patients’ clinical information and tumour-specific biomarkers status. Among these biomarkers, programmed death-ligand 1, tumour-infiltrating lymphocytes, microsatellite instability, mismatch repair and tumour mutational burden have been widely investigated. However, novel tumour-specific biomarkers and testing methods will further improve patients’ outcomes. Here, we discuss the currently available strategies for the implementation of a precision immunotherapy approach in the clinical management of metastatic solid tumours and highlight future perspectives.

Related Articles

Julia Challinor, Alan Davidson, Guillermo Chantada, Rejin Kebudi, Kathy Pritchard-Jones
Vanita Noronha, Laboni Sarkar, Vijay Patil, Nandini Menon, Minit Shah, Akash Pawar, Oindrila Roy Chowdhury, Omshree Shetty, Anuradha Chougule, Pratik Chandrani, Rajiv Kaushal, Trupti Pai, Amit Janu, Nivedita Chakrabarty, Kumar Prabhash
Monika Lokhande, Sivaranjini Kannusamy, Amey Oak, Sandhya Cheulkar, Shalmali Chavan, Varsha Mishra, Pragati Gode, Aijimol S Thakadiyil, Saket Mendhe, Supriya Kadam, Ganesh Balasubramaniam, Pankaj Chaturvedi, Rajesh Dikshit